Publications by authors named "Gregoire Nowacki"
Article Synopsis
- In Japan, there are different inhaler combinations for treating chronic obstructive pulmonary disease (COPD), including single-inhaler and multiple-inhaler triple therapies, but there is limited information about how patients are actually treated in real-life scenarios.
- This study reviewed data from COPD patients in Japan from May 2018 to December 2021, categorizing them into four groups based on the triple therapy they started, including early adopters of a specific therapy and users of other available combinations.
- The findings revealed that a high percentage of patients had asthma as a comorbidity, and around 14% to 18% experienced moderate to severe exacerbations in the year before starting treatment, indicating significant healthcare resource utilization
To describe patient and treatment characteristics associated with bevacizumab BS-Pfizer, rituximab BS-Pfizer and trastuzumab BS-Pfizer and their reference products in Japan. This retrospective observational study used an administrative claims database to identify patients with ≥1 biosimilar or reference product prescription from 2019 to 2022 for approved indications. Descriptive statistics were calculated.
View Article and Find Full Text PDFArticle Synopsis
- * The study tracked newly diagnosed CHB patients (1,973 total) for an average of 3.1 years; only 15% received treatment, mostly with Entecavir, and there were notable occurrences of severe complications like compensated and decompensated cirrhosis and hepatocellular carcinoma.
- * The economic impact is substantial, with annual healthcare costs averaging over 870,000 JPY (about 7,800 USD) per